COLL vs VTR · P/E 17, rev $181.9M vs P/E 149, rev $4.92B
Collegium Pharmaceutical Inc (COLL) versus Ventas Inc (VTR) — a side-by-side from cached financials, not a winner call.
Collegium Pharmaceutical Inc (COLL) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Ventas Inc (VTR) is a reit - healthcare facilities company listed on NYSE.
Latest reported COLL revenue for 2024-12-31 was $181.9M. Net income was $69.2M. Revenue was up 14.2% from 2024-09-30 to 2024-12-31. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
Latest reported VTR revenue for 2024-12-31 was $4.92B. Net income was $88.4M. Revenue was up 9.5% from 2023-12-31 to 2024-12-31. VTR currently screens at market cap $39.94B and trailing P/E 149.4.
COLL currently screens at market cap $1.12B and trailing P/E 16.8. VTR currently screens at market cap $39.94B and trailing P/E 149.4.
Not investment advice. Open the COLL and VTR stock pages for the full models.
Not investment advice.